1st Patient Dosed in Ph 2b Study of CyanVac`s COVID-19 Vaccine
09 Dec 2024 //
BUSINESSWIRE
Blue Lake and CyanVac Present at Society for Vaccines Congress
21 Oct 2024 //
BUSINESSWIRE
CyanVac Receives BARDA-Funded Project NextGen Award Intranasal COVID-19
13 Jun 2024 //
BUSINESSWIRE
PIV5-based Intranasal Vaccine Against Lyme Disease Demonstrates Durable Response
15 Feb 2024 //
BUSINESSWIRE
CyanVac CEO Speaks at White House Summit on the Future of COVID-19 Vaccines
27 Jul 2022 //
PRNEWSWIRE
CyanVac Announces Data from PC Studies of COVID-19 Vaccine Candidate CVXGA1
09 Jun 2022 //
PRNEWSWIRE